GSK struck a multi‑year strategic collaboration with Helix to access GenoSphere, Helix’s clinico‑genomic database of whole‑exome sequencing linked to longitudinal medical, pharmacy and mortality claims. GSK will leverage cohorts within the 300,000‑record resource to support precision‑medicine research across autoimmune, cardiometabolic and renal indications, the companies said. GSK framed the pact as part of its push to integrate genetics and genomics into R&D decision‑making; Helix emphasized consented cohorts and recontact capability. Financial terms were not disclosed. The agreement signals continued pharma interest in partnering with direct‑to‑consumer and clinical genomics providers to accelerate target identification and cohort selection for precision trials.